Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 1, 2010, Pages 75-81

  Becker, Matthijs L ^a   Visser, Loes E ^a   Van Schaik, Ron H N ^a,b   Hofman, Albert ^a,c   Uitterlinden, André G ^a,c   Stricker, Bruno H Ch ^a,c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Medical Diagnostic Center   (Netherlands)

^c Netherlands Consortium on Healthy Aging   (Netherlands)

^d Drug Safety Unit   (Netherlands)

Author keywords

ABCB1; Atorvastatin; CYP3A4; Pharmacogenetics; Simvastatin

Indexed keywords

ABC TRANSPORTER A1; ACIPIMOX; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; CYTOCHROME P450 3A4; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; SIMVASTATIN;

ALLELE; ALLERGY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAIR LOSS; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NEUROPATHY; PAIN; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; WILD TYPE;

AGED; AGED, 80 AND OVER; ALLELES; CHOLESTEROL; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DATABASES, FACTUAL; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PYRROLES; SEX FACTORS; SIMVASTATIN;

EID: 75749109736     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1866     Document Type: Article

References (29)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
2. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370(9601): 1781-1790.
3. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94(9): 1140-1146.
4. Flockhart DA. Drug Interactions: cytochrome P450 Drug Interaction Table. Indiana University School of Medicine; August 2007. http://medicine.iupui.edu/ flockhart/table.htm [accessed 28 January 2009].
5. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25(10): 1191-1199.
6. JacobsenW, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000; 28(11): 1369-1378.
7. Neuvonen PJ, Niemi M, Backman JT., Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80(6): 565-581.
8. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolismmonograph for physicians. Arch Intern Med 2000; 160(15): 2273-2280.
9. Zineh I. HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Medicine 2005; 1(2): 191-206.
10. Amirimani B, Ning B, Deitz AC, et al. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42(4): 299-305.
11. Westlind A, Löfberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP. A4: relationship to genetic polymorphism in the 50′- upstream regulatory region. Biochem Biophys Res Commun 1999; 259(1): 201-205.
12. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90(16): 1225-1229.
13. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95(22): 13176-13181.
14. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74(3): 245-254.
15. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004; 277(1-2): 3-9.
16. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by Pglycoprotein. Clin Pharmacol Ther 2002; 72(5): 474-489.
17. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75(1): 13-33.
18. Hofman A, Breteler MM, van Duijn CM, et al. The Rotterdam study: objectives and design update. Eur J Epidemiol 2007; 22(11): 819-829.
19. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7(4): 403-422.
20. WHO. Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2009. Oslo, 2009. http://www.whocc.no/atcddd/indexdatabase/ [accessed 28 January 2009].
21. Fang Y, van Meurs JB, d'Alesio A, et al. Promoter and 3'-untranslatedregion haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam Study. Am J Hum Genet 2005; 77(5): 807-823.
22. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93(1): 104-107.
23. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78(5): 551-558.
24. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004; 93(8): 1046-1050.
25. Aarnoudse AL, van Schaik RH, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 2006; 80(4): 367-374.
26. Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 2008; 18(4): 299-305.
27. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24(5): 339-346.
28. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199(3): 193-209.
29. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270(1): 414-423.